TransCode Therapeutics OverviewTransCode Therapeutics EBIT
EBIT (Earnings Before Interest and Taxes) analysis for RNAZ.
Quarterly EBIT
$0.00
As of Mar 31, 2026
Annual EBIT (TTM)
$12.09M
↑ 209.59% YoY
Trailing 12 months ending Mar 31, 2026
TransCode Therapeutics OverviewEBIT (Earnings Before Interest and Taxes) analysis for RNAZ.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026